Novel Histone Deacetylase Inhibitor Modulates Cardiac Peroxisome Proliferator-Activated Receptors and Inflammatory Cytokines in Heart Failure

Baigalmaa Lkhagva, Yung Kuo Lin, Yu Hsun Kao, Tze Fan Chazo, Cheng Chih Chung, Shih Ann Chen, Yi Jen Chen

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Heart failure (HF) affects cardiac metabolism and inflammation. Histone deacetylases (HDACs) play a critical role in cardiac pathophysiology. This study investigated whether HDAC inhibition can regulate HF by modifying cardiac inflammation and peroxisome proliferator-activated receptor (PPAR) isoforms. Methods: Echocardiography, electrocardiography, ELISA and Western blot were performed in rats with isoproterenol-induced HF, with and without orally administered MPT0E014 (a novel HDAC inhibitor, 50 mg/kg for 7 consecutive days). Results: The left ventricles (LVs) of HF rats expressed significantly higher levels of HDAC1, HDAC2, HDAC3, HDAC4 and HDAC6 than the healthy LVs did. HF rats treated with MPT0E014 exhibited improved cardiac fraction shortening with reducing chamber size. The MPT0E014-treated HF LVs exhibited a smaller increase in the expression of interleukin (IL)-6, p22, SMAD2/3, extracellular signal-regulated kinase 1/2, PPAR isoforms and circulatory tumor growth factor-β1 than the untreated HF LVs did. Moreover, MPT0E014-treated HF LVs expressed less fibroblast growth factor receptor than untreated HF LVs did. Conclusions: HDAC inhibition can improve cardiac function and attenuate the effects of HF on cardiac metabolism and inflammation, which might contribute to the beneficial effects of HDAC inhibition in HF.

Original languageEnglish
Pages (from-to)184-191
Number of pages8
JournalPharmacology
Volume96
Issue number3-4
DOIs
Publication statusPublished - Sep 8 2015

Fingerprint

Peroxisome Proliferator-Activated Receptors
Histone Deacetylase Inhibitors
Heart Failure
Cytokines
Histone Deacetylases
Heart Ventricles
Inflammation
Protein Isoforms
Fibroblast Growth Factor Receptors
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 1
Isoproterenol
Echocardiography
Interleukin-6
Intercellular Signaling Peptides and Proteins
Electrocardiography
Western Blotting
Enzyme-Linked Immunosorbent Assay

Keywords

  • Fibroblast growth factor
  • Heart failure
  • Histone deacetylase inhibitor
  • Inflammation

ASJC Scopus subject areas

  • Pharmacology

Cite this

Novel Histone Deacetylase Inhibitor Modulates Cardiac Peroxisome Proliferator-Activated Receptors and Inflammatory Cytokines in Heart Failure. / Lkhagva, Baigalmaa; Lin, Yung Kuo; Kao, Yu Hsun; Chazo, Tze Fan; Chung, Cheng Chih; Chen, Shih Ann; Chen, Yi Jen.

In: Pharmacology, Vol. 96, No. 3-4, 08.09.2015, p. 184-191.

Research output: Contribution to journalArticle

@article{474f55272e95492e8ce44ab2f4c1c824,
title = "Novel Histone Deacetylase Inhibitor Modulates Cardiac Peroxisome Proliferator-Activated Receptors and Inflammatory Cytokines in Heart Failure",
abstract = "Background: Heart failure (HF) affects cardiac metabolism and inflammation. Histone deacetylases (HDACs) play a critical role in cardiac pathophysiology. This study investigated whether HDAC inhibition can regulate HF by modifying cardiac inflammation and peroxisome proliferator-activated receptor (PPAR) isoforms. Methods: Echocardiography, electrocardiography, ELISA and Western blot were performed in rats with isoproterenol-induced HF, with and without orally administered MPT0E014 (a novel HDAC inhibitor, 50 mg/kg for 7 consecutive days). Results: The left ventricles (LVs) of HF rats expressed significantly higher levels of HDAC1, HDAC2, HDAC3, HDAC4 and HDAC6 than the healthy LVs did. HF rats treated with MPT0E014 exhibited improved cardiac fraction shortening with reducing chamber size. The MPT0E014-treated HF LVs exhibited a smaller increase in the expression of interleukin (IL)-6, p22, SMAD2/3, extracellular signal-regulated kinase 1/2, PPAR isoforms and circulatory tumor growth factor-β1 than the untreated HF LVs did. Moreover, MPT0E014-treated HF LVs expressed less fibroblast growth factor receptor than untreated HF LVs did. Conclusions: HDAC inhibition can improve cardiac function and attenuate the effects of HF on cardiac metabolism and inflammation, which might contribute to the beneficial effects of HDAC inhibition in HF.",
keywords = "Fibroblast growth factor, Heart failure, Histone deacetylase inhibitor, Inflammation",
author = "Baigalmaa Lkhagva and Lin, {Yung Kuo} and Kao, {Yu Hsun} and Chazo, {Tze Fan} and Chung, {Cheng Chih} and Chen, {Shih Ann} and Chen, {Yi Jen}",
year = "2015",
month = "9",
day = "8",
doi = "10.1159/000438864",
language = "English",
volume = "96",
pages = "184--191",
journal = "Pharmacology",
issn = "0031-7012",
publisher = "S. Karger AG",
number = "3-4",

}

TY - JOUR

T1 - Novel Histone Deacetylase Inhibitor Modulates Cardiac Peroxisome Proliferator-Activated Receptors and Inflammatory Cytokines in Heart Failure

AU - Lkhagva, Baigalmaa

AU - Lin, Yung Kuo

AU - Kao, Yu Hsun

AU - Chazo, Tze Fan

AU - Chung, Cheng Chih

AU - Chen, Shih Ann

AU - Chen, Yi Jen

PY - 2015/9/8

Y1 - 2015/9/8

N2 - Background: Heart failure (HF) affects cardiac metabolism and inflammation. Histone deacetylases (HDACs) play a critical role in cardiac pathophysiology. This study investigated whether HDAC inhibition can regulate HF by modifying cardiac inflammation and peroxisome proliferator-activated receptor (PPAR) isoforms. Methods: Echocardiography, electrocardiography, ELISA and Western blot were performed in rats with isoproterenol-induced HF, with and without orally administered MPT0E014 (a novel HDAC inhibitor, 50 mg/kg for 7 consecutive days). Results: The left ventricles (LVs) of HF rats expressed significantly higher levels of HDAC1, HDAC2, HDAC3, HDAC4 and HDAC6 than the healthy LVs did. HF rats treated with MPT0E014 exhibited improved cardiac fraction shortening with reducing chamber size. The MPT0E014-treated HF LVs exhibited a smaller increase in the expression of interleukin (IL)-6, p22, SMAD2/3, extracellular signal-regulated kinase 1/2, PPAR isoforms and circulatory tumor growth factor-β1 than the untreated HF LVs did. Moreover, MPT0E014-treated HF LVs expressed less fibroblast growth factor receptor than untreated HF LVs did. Conclusions: HDAC inhibition can improve cardiac function and attenuate the effects of HF on cardiac metabolism and inflammation, which might contribute to the beneficial effects of HDAC inhibition in HF.

AB - Background: Heart failure (HF) affects cardiac metabolism and inflammation. Histone deacetylases (HDACs) play a critical role in cardiac pathophysiology. This study investigated whether HDAC inhibition can regulate HF by modifying cardiac inflammation and peroxisome proliferator-activated receptor (PPAR) isoforms. Methods: Echocardiography, electrocardiography, ELISA and Western blot were performed in rats with isoproterenol-induced HF, with and without orally administered MPT0E014 (a novel HDAC inhibitor, 50 mg/kg for 7 consecutive days). Results: The left ventricles (LVs) of HF rats expressed significantly higher levels of HDAC1, HDAC2, HDAC3, HDAC4 and HDAC6 than the healthy LVs did. HF rats treated with MPT0E014 exhibited improved cardiac fraction shortening with reducing chamber size. The MPT0E014-treated HF LVs exhibited a smaller increase in the expression of interleukin (IL)-6, p22, SMAD2/3, extracellular signal-regulated kinase 1/2, PPAR isoforms and circulatory tumor growth factor-β1 than the untreated HF LVs did. Moreover, MPT0E014-treated HF LVs expressed less fibroblast growth factor receptor than untreated HF LVs did. Conclusions: HDAC inhibition can improve cardiac function and attenuate the effects of HF on cardiac metabolism and inflammation, which might contribute to the beneficial effects of HDAC inhibition in HF.

KW - Fibroblast growth factor

KW - Heart failure

KW - Histone deacetylase inhibitor

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=84940704313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940704313&partnerID=8YFLogxK

U2 - 10.1159/000438864

DO - 10.1159/000438864

M3 - Article

C2 - 26304494

AN - SCOPUS:84940704313

VL - 96

SP - 184

EP - 191

JO - Pharmacology

JF - Pharmacology

SN - 0031-7012

IS - 3-4

ER -